News
Asianet Newsable on MSN46m
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s SoldBimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback